11 results on '"Crull D"'
Search Results
2. ASO Author Reflections: Improvement of Esophageal Cancer Staging by Implementing Mandard Tumor Regression Score
- Author
-
Crull, D. J., Hogenes, M. C. H., Hoekstra, R., Hendriksen, E. M., van Det, M. J., and Kouwenhoven, E. A.
- Published
- 2022
- Full Text
- View/download PDF
3. ASO Visual Abstract: The Impact of Tumor Regression on Prognosis After Neoadjuvant Chemoradiotherapy in Surgically Treated Esophageal Adenocarcinoma
- Author
-
Crull, D. J., Hogenes, M. C. H., Hoekstra, R., Hendriksen, E. M., van Det, M. J., and Kouwenhoven, E. A.
- Published
- 2022
- Full Text
- View/download PDF
4. Trends in Distal Esophageal and Gastroesophageal Junction Cancer Care: The Dutch Nationwide Ivory Study.
- Author
-
Kalff, M.C., Berge Henegouwen, M.I. van, Baas, P.C., Bahadoer, R.R., Belt, E.J., Brattinga, B., Claassen, L., Ćosović, A., Crull, D., Daams, F., Dalsen, A.D. van, Dekker, J.W.T., Det, M.J. van, Drost, M., Duijvendijk, P. van, Eshuis, W.J., Esser, S. van, Gaspersz, M.P., Görgec, B., Groenendijk, R.P.R., Hartgrink, H.H., Harst, E, Haveman, J.W., Heisterkamp, J., Hillegersberg, R. van, Kelder, W., Kingma, B.F., Koemans, W.J., Kouwenhoven, E.A., Lagarde, S.M., Lecot, F., Linden, P.P. van der, Luyer, M.D., Nieuwenhuijzen, G.A., Olthof, P.B., Peet, D.L. van der, Pierie, J.E.N., Pierik, E.G.J.M.R., Plat, V.D., Polat, F., Rosman, C., Ruurda, J.P., Sandick, J.W. van, Scheer, R., Slootmans, C.A.M., Sosef, M.N., Sosef, O.V., Steur, W.O. de, Stockmann, H.B., Stoop, F.J., Voeten, D.M., Vugts, G., Vijgen, G.H.E.J., Weeda, V.B., Wiezer, M.J., Oijen, M.G. van, Gisbertz, S.S., Kalff, M.C., Berge Henegouwen, M.I. van, Baas, P.C., Bahadoer, R.R., Belt, E.J., Brattinga, B., Claassen, L., Ćosović, A., Crull, D., Daams, F., Dalsen, A.D. van, Dekker, J.W.T., Det, M.J. van, Drost, M., Duijvendijk, P. van, Eshuis, W.J., Esser, S. van, Gaspersz, M.P., Görgec, B., Groenendijk, R.P.R., Hartgrink, H.H., Harst, E, Haveman, J.W., Heisterkamp, J., Hillegersberg, R. van, Kelder, W., Kingma, B.F., Koemans, W.J., Kouwenhoven, E.A., Lagarde, S.M., Lecot, F., Linden, P.P. van der, Luyer, M.D., Nieuwenhuijzen, G.A., Olthof, P.B., Peet, D.L. van der, Pierie, J.E.N., Pierik, E.G.J.M.R., Plat, V.D., Polat, F., Rosman, C., Ruurda, J.P., Sandick, J.W. van, Scheer, R., Slootmans, C.A.M., Sosef, M.N., Sosef, O.V., Steur, W.O. de, Stockmann, H.B., Stoop, F.J., Voeten, D.M., Vugts, G., Vijgen, G.H.E.J., Weeda, V.B., Wiezer, M.J., Oijen, M.G. van, and Gisbertz, S.S.
- Abstract
Item does not contain fulltext, OBJECTIVE: This study evaluated the nationwide trends in care and accompanied postoperative outcomes for patients with distal esophageal and gastro-esophageal junction cancer. SUMMARY OF BACKGROUND DATA: The introduction of transthoracic esophagectomy, minimally invasive surgery, and neo-adjuvant chemo(radio)therapy changed care for patients with esophageal cancer. METHODS: Patients after elective transthoracic and transhiatal esophagectomy for distal esophageal or gastroesophageal junction carcinoma in the Netherlands between 2007-2016 were included. The primary aim was to evaluate trends in both care and postoperative outcomes for the included patients. Additionally, postoperative outcomes after transthoracic and tran-shiatal esophagectomy were compared, stratified by time periods. RESULTS: Among 4712 patients included, 74% had distal esophageal tumors and 87% had adenocarcinomas. Between 2007 and 2016, the proportion of transthoracic esophagectomy increased from 41% to 81%, and neo-adjuvant treatment and minimally invasive esophagectomy increased from 31% to 96%, and from 7% to 80%, respectively. Over this 10-year period, postoperative outcomes improved: postoperative morbidity decreased from 66.6% to 61.8% ( P = 0.001), R0 resection rate increased from 90.0% to 96.5% (P <0.001), median lymph node harvest increased from 15 to 19 ( P <0.001), and median survival increased from 35 to 41 months ( P = 0.027). CONCLUSION: In this nationwide cohort, a transition towards more neo-adju-vant treatment, transthoracic esophagectomy and minimally invasive surgery was observed over a 10-year period, accompanied by decreased postoperative morbidity, improved surgical radicality and lymph node harvest, and improved survival.
- Published
- 2023
5. Recurrent Disease After Esophageal Cancer Surgery: A Substudy of The Dutch Nationwide Ivory Study
- Author
-
Kalff, M.C., Henckens, S.P.G., Voeten, D.M., Heineman, D.J., Hulshof, M., Laarhoven, H.W.M. van, Eshuis, W.J., Baas, P.C., Bahadoer, R.R., Belt, E.J., Brattinga, B., Claassen, L., Ćosović, A., Crull, D., Daams, F., Dalsen, A.D. van, Dekker, J.W.T., Det, M.J. van, Drost, M., Duijvendijk, P. van, Esser, S. van, Gaspersz, M.P., Görgec, B., Groenendijk, R.P.R., Hartgrink, H.H., Harst, E, Haveman, J.W., Heisterkamp, J., Hillegersberg, R. van, Kelder, W., Kingma, B.F., Koemans, W.J., Kouwenhoven, E.A., Lagarde, S.M., Lecot, F., Linden, P.P. van der, Luyer, M.D., Nieuwenhuijzen, G.A., Olthof, P.B., Peet, D.L. van der, Pierie, J.E.N., Pierik, E., Plat, V.D., Polat, Fatih, Rosman, C., Ruurda, J.P., Sandick, J.W. van, Scheer, R., Slootmans, C.A.M., Sosef, M.N., Sosef, O.V., Steur, W.O. de, Stockmann, H., Stoop, F.J., Vugts, G., Vijgen, G., Weeda, V.B., Wiezer, M.J., Oijen, M.G. van, Henegouwen, M.I. van Berge, Gisbertz, S.S., Kalff, M.C., Henckens, S.P.G., Voeten, D.M., Heineman, D.J., Hulshof, M., Laarhoven, H.W.M. van, Eshuis, W.J., Baas, P.C., Bahadoer, R.R., Belt, E.J., Brattinga, B., Claassen, L., Ćosović, A., Crull, D., Daams, F., Dalsen, A.D. van, Dekker, J.W.T., Det, M.J. van, Drost, M., Duijvendijk, P. van, Esser, S. van, Gaspersz, M.P., Görgec, B., Groenendijk, R.P.R., Hartgrink, H.H., Harst, E, Haveman, J.W., Heisterkamp, J., Hillegersberg, R. van, Kelder, W., Kingma, B.F., Koemans, W.J., Kouwenhoven, E.A., Lagarde, S.M., Lecot, F., Linden, P.P. van der, Luyer, M.D., Nieuwenhuijzen, G.A., Olthof, P.B., Peet, D.L. van der, Pierie, J.E.N., Pierik, E., Plat, V.D., Polat, Fatih, Rosman, C., Ruurda, J.P., Sandick, J.W. van, Scheer, R., Slootmans, C.A.M., Sosef, M.N., Sosef, O.V., Steur, W.O. de, Stockmann, H., Stoop, F.J., Vugts, G., Vijgen, G., Weeda, V.B., Wiezer, M.J., Oijen, M.G. van, Henegouwen, M.I. van Berge, and Gisbertz, S.S.
- Abstract
Item does not contain fulltext, OBJECTIVE: This study investigated the patterns, predictors, and survival of recurrent disease following esophageal cancer surgery. BACKGROUND: Survival of recurrent esophageal cancer is usually poor, with limited prospects of remission. METHODS: This nationwide cohort study included patients with distal esophageal and gastroesophageal junction adenocarcinoma and squamous cell carcinoma after curatively intended esophagectomy in 2007 to 2016 (follow-up until January 2020). Patients with distant metastases detected during surgery were excluded. Univariable and multivariable logistic regression were used to identify predictors of recurrent disease. Multivariable Cox regression was used to determine the association of recurrence site and treatment intent with postrecurrence survival. RESULTS: Among 4626 patients, 45.1% developed recurrent disease a median of 11 months postoperative, of whom most had solely distant metastases (59.8%). Disease recurrences were most frequently hepatic (26.2%) or pulmonary (25.1%). Factors significantly associated with disease recurrence included young age (≤65 y), male sex, adenocarcinoma, open surgery, transthoracic esophagectomy, nonradical resection, higher T-stage, and tumor positive lymph nodes. Overall, median postrecurrence survival was 4 months [95% confidence interval (95% CI): 3.6-4.4]. After curatively intended recurrence treatment, median survival was 20 months (95% CI: 16.4-23.7). Survival was more favorable after locoregional compared with distant recurrence (hazard ratio: 0.74, 95% CI: 0.65-0.84). CONCLUSIONS: This study provides important prognostic information assisting in the surveillance and counseling of patients after curatively intended esophageal cancer surgery. Nearly half the patients developed recurrent disease, with limited prospects of survival. The risk of recurrence was higher in patients with a higher tumor stage, nonradical resection and positive lymph node harvest.
- Published
- 2022
6. 510 IMPACT OF TUMOR REGRESSION ON PROGNOSIS AFTER NEOADJUVANT CHEMORADIOTHERAPY IN MINIMALLY INVASIVE ESOPHAGECTOMY TREATED ESOPHAGEAL ADENOCARCINOMA
- Author
-
Crull, D, primary, Hogenes, M, additional, van Det, M, additional, and Kouwenhoven, E, additional
- Published
- 2020
- Full Text
- View/download PDF
7. Complication Prediction after Esophagectomy with Machine Learning.
- Author
-
van de Beld JJ, Crull D, Mikhal J, Geerdink J, Veldhuis A, Poel M, and Kouwenhoven EA
- Abstract
Esophageal cancer can be treated effectively with esophagectomy; however, the postoperative complication rate is high. In this paper, we study to what extent machine learning methods can predict anastomotic leakage and pneumonia up to two days in advance. We use a dataset with 417 patients who underwent esophagectomy between 2011 and 2021. The dataset contains multimodal temporal information, specifically, laboratory results, vital signs, thorax images, and preoperative patient characteristics. The best models scored mean test set AUROCs of 0.87 and 0.82 for leakage 1 and 2 days ahead, respectively. For pneumonia, this was 0.74 and 0.61 for 1 and 2 days ahead, respectively. We conclude that machine learning models can effectively predict anastomotic leakage and pneumonia after esophagectomy.
- Published
- 2024
- Full Text
- View/download PDF
8. Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma.
- Author
-
Henckens SPG, Liu D, Gisbertz SS, Kalff MC, Anderegg MCJ, Crull D, Daams F, van Dalsen AD, Dekker JWT, van Det MJ, van Duijvendijk P, Eshuis WJ, Groenendijk RPR, Haveman JW, van Hillegersberg R, Luyer MDP, Olthof PB, Pierie JEN, Plat VD, Rosman C, Ruurda JP, van Sandick JW, Sosef MN, Voeten DM, Vijgen GHEJ, Bijlsma MF, Meijer SL, Hulshof MCCM, Oyarce C, Lagarde SM, van Laarhoven HWM, and van Berge Henegouwen MI
- Subjects
- Humans, Prognosis, Cohort Studies, Disease-Free Survival, Combined Modality Therapy, Esophageal Neoplasms, Adenocarcinoma
- Abstract
Background: This study evaluated the association of pathological tumour response (tumour regression grade, TRG) and a novel scoring system, combining both TRG and nodal status (TRG-ypN score; TRG1-ypN0, TRG>1-ypN0, TRG1-ypN+ and TRG>1-ypN+), with recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma., Methods: This Dutch nationwide cohort study included patients treated with neoadjuvant chemoradiotherapy followed by oesophagectomy for distal oesophageal or gastro-oesophageal junctional adenocarcinoma between 2007 and 2016. The primary endpoint was the association of Mandard score and TRG-ypN score with recurrence patterns (rate, location, and time to recurrence). The secondary endpoint was overall survival., Results: Among 2746 inclusions, recurrence rates increased with higher Mandard scores (TRG1 30.6%, TRG2 44.9%, TRG3 52.9%, TRG4 61.4%, TRG5 58.2%; P < 0.001). Among patients with recurrent disease, the distribution (locoregional versus distant) was the same for the different TRG groups. Patients with TRG1 developed more brain recurrences (17.7 versus 9.8%; P = 0.001) and had a longer mean overall survival (44 versus 35 months; P < 0.001) than those with TRG>1. The TRG>1-ypN+ group had the highest recurrence rate (64.9%) and worst overall survival (mean 27 months). Compared with the TRG>1-ypN0 group, patients with TRG1-ypN+ had a higher risk of recurrence (51.9 versus 39.6%; P < 0.001) and worse mean overall survival (33 versus 41 months; P < 0.001)., Conclusion: Improved tumour response to neoadjuvant therapy was associated with lower recurrence rates and higher overall survival rates. Among patients with recurrent disease, TRG1 was associated with a higher incidence of brain recurrence than TRG>1. Residual nodal disease influenced prognosis more negatively than residual disease at the primary tumour site., (© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
9. Trends in Distal Esophageal and Gastroesophageal Junction Cancer Care: The Dutch Nationwide Ivory Study.
- Author
-
Kalff MC, van Berge Henegouwen MI, Baas PC, Bahadoer RR, Belt EJT, Brattinga B, Claassen L, Ćosović A, Crull D, Daams F, van Dalsen AD, Dekker JWT, van Det MJ, Drost M, van Duijvendijk P, Eshuis WJ, van Esser S, Gaspersz MP, Görgec B, Groenendijk RPR, Hartgrink HH, van der Harst E, Haveman JW, Heisterkamp J, van Hillegersberg R, Kelder W, Kingma BF, Koemans WJ, Kouwenhoven EA, Lagarde SM, Lecot F, van der Linden PP, Luyer MDP, Nieuwenhuijzen GAP, Olthof PB, van der Peet DL, Pierie JEN, Pierik EGJMR, Plat VD, Polat F, Rosman C, Ruurda JP, van Sandick JW, Scheer R, Slootmans CAM, Sosef MN, Sosef OV, de Steur WO, Stockmann HBAC, Stoop FJ, Voeten DM, Vugts G, Vijgen GHEJ, Weeda VB, Wiezer MJ, van Oijen MGH, and Gisbertz SS
- Subjects
- Humans, Lymph Nodes pathology, Esophagogastric Junction surgery, Esophagogastric Junction pathology, Lymph Node Excision, Esophagectomy adverse effects, Postoperative Complications etiology, Treatment Outcome, Adenocarcinoma surgery, Esophageal Neoplasms surgery, Stomach Neoplasms surgery
- Abstract
Objective: This study evaluated the nationwide trends in care and accompanied postoperative outcomes for patients with distal esophageal and gastro-esophageal junction cancer., Summary of Background Data: The introduction of transthoracic esophagectomy, minimally invasive surgery, and neo-adjuvant chemo(radio)therapy changed care for patients with esophageal cancer., Methods: Patients after elective transthoracic and transhiatal esophagectomy for distal esophageal or gastroesophageal junction carcinoma in the Netherlands between 2007-2016 were included. The primary aim was to evaluate trends in both care and postoperative outcomes for the included patients. Additionally, postoperative outcomes after transthoracic and tran-shiatal esophagectomy were compared, stratified by time periods., Results: Among 4712 patients included, 74% had distal esophageal tumors and 87% had adenocarcinomas. Between 2007 and 2016, the proportion of transthoracic esophagectomy increased from 41% to 81%, and neo-adjuvant treatment and minimally invasive esophagectomy increased from 31% to 96%, and from 7% to 80%, respectively. Over this 10-year period, postoperative outcomes improved: postoperative morbidity decreased from 66.6% to 61.8% ( P = 0.001), R0 resection rate increased from 90.0% to 96.5% (P <0.001), median lymph node harvest increased from 15 to 19 ( P <0.001), and median survival increased from 35 to 41 months ( P = 0.027)., Conclusion: In this nationwide cohort, a transition towards more neo-adju-vant treatment, transthoracic esophagectomy and minimally invasive surgery was observed over a 10-year period, accompanied by decreased postoperative morbidity, improved surgical radicality and lymph node harvest, and improved survival., Competing Interests: Luyer received research grants from Galvani and Medtronic. Nieuwenhuijzen reports consulting fees and research grants from Medtronic. Rosman has received research grants from Johnson&Johnson and Medtronic. van Berge Henegouwen reports research grants from Olympus and Stryker, in addition to consulting fees from Medtronic, Alesi Surgical, Johnson&Johnson and Mylan. van Oijen has received unrestricted research grants from Bayer, Lilly, Merck Serono, Nordic, Servier, and Roche. The remaining authors have no conflict of interest to report. No funding was received for this study., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
10. Suction Drainage for Anastomotic Leakage After Ivor Lewis Esophagectomy.
- Author
-
Lubbers M, van Det MJ, Crull D, van der Linden A, Vrij AA, and Kouwenhoven EA
- Subjects
- Humans, Suction, Esophagectomy adverse effects, Esophagectomy methods, Postoperative Complications etiology, Postoperative Complications surgery, Retrospective Studies, Anastomosis, Surgical adverse effects, Anastomosis, Surgical methods, Anastomotic Leak etiology, Anastomotic Leak surgery, Esophageal Neoplasms surgery
- Abstract
Background: Anastomotic leakage is one of the most life-threatening complications after Ivor Lewis esophagectomy (ILE), with various treatment strategies. Endoscopic techniques are emerging as a less invasive alternative to surgery. Among the current endoscopic techniques, a single placement of an endoluminal nasogastric tube inside the cavity with controlled suction drainage (SD) seems to be an attractive option. The aim of this study was to evaluate the efficacy of SD as treatment for anastomotic leakage after ILE., Methods: This retrospective analysis was performed among patients who underwent ILE in a high-volume esophageal cancer center in the Netherlands. Patients with an anastomotic leakage that received SD as primary treatment were selected. A nasogastric tube was endoscopically placed into the cavity of the leakage for controlled suction with 15 mm Hg., Results: A total of 34 patients received SD and was successful in 26 patients (77%). Seven patients (21%) developed empyema despite the SD for which additional video-assisted thoracoscopic surgery was performed. Mortality was 5.9% (2 patients) and median intensive care unit and hospital stay were 3 days (1 to 9) and 25 days (14 to 43), respectively. The median time to closure of the leak was 41 days (23 to 65). A total of 16 patients underwent home treatment for a median of 23 (14 to 42) days., Conclusions: Controlled SD seems to be an effective treatment for anastomotic leakage after ILE. This therapy can safely and effectively be completed in an ambulant, outpatient setting., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
11. Recurrent Disease After Esophageal Cancer Surgery: A Substudy of The Dutch Nationwide Ivory Study.
- Author
-
Kalff MC, Henckens SPG, Voeten DM, Heineman DJ, Hulshof MCCM, van Laarhoven HWM, Eshuis WJ, Baas PC, Bahadoer RR, Belt EJT, Brattinga B, Claassen L, Ćosović A, Crull D, Daams F, van Dalsen AD, Dekker JWT, van Det MJ, Drost M, van Duijvendijk P, van Esser S, Gaspersz MP, Görgec B, Groenendijk RPR, Hartgrink HH, van der Harst E, Haveman JW, Heisterkamp J, van Hillegersberg R, Kelder W, Kingma BF, Koemans WJ, Kouwenhoven EA, Lagarde SM, Lecot F, van der Linden PP, Luyer MDP, Nieuwenhuijzen GAP, Olthof PB, van der Peet DL, Pierie JEN, Pierik EGJMR, Plat VD, Polat F, Rosman C, Ruurda JP, van Sandick JW, Scheer R, Slootmans CAM, Sosef MN, Sosef OV, de Steur WO, Stockmann HBAC, Stoop FJ, Vugts G, Vijgen GHEJ, Weeda VB, Wiezer MJ, van Oijen MGH, van Berge Henegouwen MI, and Gisbertz SS
- Subjects
- Cohort Studies, Esophagectomy, Humans, Lymphatic Metastasis, Male, Neoplasm Recurrence, Local pathology, Prognosis, Retrospective Studies, Survival Rate, Adenocarcinoma pathology, Esophageal Neoplasms
- Abstract
Objective: This study investigated the patterns, predictors, and survival of recurrent disease following esophageal cancer surgery., Background: Survival of recurrent esophageal cancer is usually poor, with limited prospects of remission., Methods: This nationwide cohort study included patients with distal esophageal and gastroesophageal junction adenocarcinoma and squamous cell carcinoma after curatively intended esophagectomy in 2007 to 2016 (follow-up until January 2020). Patients with distant metastases detected during surgery were excluded. Univariable and multivariable logistic regression were used to identify predictors of recurrent disease. Multivariable Cox regression was used to determine the association of recurrence site and treatment intent with postrecurrence survival., Results: Among 4626 patients, 45.1% developed recurrent disease a median of 11 months postoperative, of whom most had solely distant metastases (59.8%). Disease recurrences were most frequently hepatic (26.2%) or pulmonary (25.1%). Factors significantly associated with disease recurrence included young age (≤65 y), male sex, adenocarcinoma, open surgery, transthoracic esophagectomy, nonradical resection, higher T-stage, and tumor positive lymph nodes. Overall, median postrecurrence survival was 4 months [95% confidence interval (95% CI): 3.6-4.4]. After curatively intended recurrence treatment, median survival was 20 months (95% CI: 16.4-23.7). Survival was more favorable after locoregional compared with distant recurrence (hazard ratio: 0.74, 95% CI: 0.65-0.84)., Conclusions: This study provides important prognostic information assisting in the surveillance and counseling of patients after curatively intended esophageal cancer surgery. Nearly half the patients developed recurrent disease, with limited prospects of survival. The risk of recurrence was higher in patients with a higher tumor stage, nonradical resection and positive lymph node harvest., Competing Interests: M.D.P.L. received research grants from Galvani and Medtronic. G.A.P.N. reports consulting fees and research grants from Medtronic. C.R. has received research grants from Johnson&Johnson and Medtronic. M.I.v.B.H. reports research grants from Olympus and Stryker, in addition to consulting fees from Medtronic, Alesi Surgical, Johnson&Johnson, and Mylan. M.G.H.v.O. has received unrestricted research grants from Bayer, Lilly, Merck Serono, Nordic, Servier, and Roche. The remaining authors report no conflicts of interest., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.